Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 6:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,275 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cancer of Ovary Clear all
Terminated Phase 1 Interventional

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

NCT04152018
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, Pancreatic Cancer, Bile Duct Cancer, Endometrial Cancer, Melanoma Cancer, Urothelial Cancer
Interventions
PF-06940434, PF-06801591
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Sep 11, 2026, 6:23 PM EDT
Completed Phase 1 Interventional

Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion

NCT01997190
View directory record Official record
Conditions
Malignant Pleural Effusion, Lung Cancer, Mesothelioma, Breast Cancer, Ovarian Cancer
Interventions
AdV-tk + valacyclovir
Biological
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 11, 2026, 6:23 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Hyperandrogenemia and Altered Day-night LH Pulse Patterns

NCT03068910
View directory record Official record
Conditions
Hyperandrogenism, Polycystic Ovary Syndrome, Puberty
Interventions
Micronized progesterone, Spironolactone, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 17 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 11, 2026, 6:23 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions
ONC-392, Pembrolizumab, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Springdale, Arkansas • Davis, California • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 11, 2026, 6:23 PM EDT
Not listed Not applicable Interventional

Iyengar Yoga Therapy for Dysmenorrhea and Endometriosis

NCT03784976
View directory record Official record
Conditions
Secondary Dysmenorrhea, Dysmenorrhea, Dysmenorrhea Secondary, Polycystic Ovary Syndrome, Endometriosis, Fibroid, Menstrual Pain, Menstrual Disorder, Menstrual Discomfort
Interventions
Iyengar Yoga Therapy
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
12 Years to 65 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 23, 2018 · Synced Sep 11, 2026, 6:23 PM EDT
Terminated Phase 2 Interventional

Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients

NCT03342417
View directory record Official record
Conditions
Breast Cancer Female, Ovarian Cancer, Gastric Cancer
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
ExcellaBio LLC
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 11, 2026, 6:23 PM EDT
Completed Phase 2 Interventional

Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum

NCT00012090
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
bicalutamide, goserelin acetate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Sep 11, 2026, 6:23 PM EDT
Recruiting Phase 2 Interventional

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

NCT06617923
View directory record Official record
Conditions
Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Interventions
Senaparib, Temozolomide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 11, 2026, 6:23 PM EDT
Terminated No phase listed Observational

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

NCT01096381
View directory record Official record
Conditions
Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 11, 2026, 6:23 PM EDT
Completed Phase 4 Interventional Results available

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

NCT01432015
View directory record Official record
Conditions
Ovarian Cancer, Uterine Cancer
Interventions
fosaprepitant, aprepitant, Oral Placebo, IV placebo
Drug · Other
Lead sponsor
Gynecologic Oncology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 11, 2026, 6:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma

NCT02601950
View directory record Official record
Conditions
Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), Selected Tumors With Rhabdoid Features, Synovial Sarcoma, INI1-negative Tumors, Malignant Rhabdoid Tumor of Ovary, Renal Medullary Carcinoma, Epithelioid Sarcoma, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Any Solid Tumor With an EZH2 GOF Mutation
Interventions
Tazemetostat
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
14
States / cities
San Francisco, California • Aurora, Colorado • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 11, 2026, 6:23 PM EDT
Not listed Phase 1 Interventional

HIPEC After Initial CRS in Patients Who Have Received NACT

NCT03540017
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
Cisplatin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 11, 2026, 6:23 PM EDT
Completed Not applicable Interventional Results available

Is it Feasible?: Self-Affirmation for Hereditary Breast and Ovarian Cancer Genetic Counseling

NCT03225170
View directory record Official record
Conditions
Breast Cancer
Interventions
Self Affirmation (SA), Control
Behavioral
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 11, 2026, 6:23 PM EDT
Completed No phase listed Observational

Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel

NCT00003569
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
Interventions
cisplatin, dimesna, paclitaxel
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Sep 11, 2026, 6:23 PM EDT
Recruiting Phase 3 Interventional

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781
View directory record Official record
Conditions
Low Grade Serous Ovarian Cancer
Interventions
avutometinib, Defactinib, Pegylated liposomal doxorubicin, Paclitaxel, Letrozole, Anastrozole
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
38
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 11, 2026, 6:23 PM EDT
Recruiting Phase 2 Interventional

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

NCT06906341
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
Interventions
Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 11, 2026, 6:23 PM EDT
Completed Phase 4 Interventional Results available

Tumor Gene Expression in Women With Ovarian Cancer

NCT00817479
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 59 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 11, 2026, 6:23 PM EDT
Recruiting Phase 1 Interventional

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

NCT05103683
View directory record Official record
Conditions
Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
Interventions
TORL-1-23
Drug
Lead sponsor
TORL Biotherapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fullerton, California • Los Angeles, California • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 11, 2026, 6:23 PM EDT
Terminated Not applicable Interventional

Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact

NCT04731441
View directory record Official record
Conditions
Colon Cancer, Ovarian Cancer, GI Cancer, Gynecologic Cancer
Interventions
Home-based Exercise Program Prior to CRS-HIPEC, Exercise Education
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 11, 2026, 6:23 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer

NCT00005051
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, cisplatin, paclitaxel, topotecan hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Fresh Meadows, New York • New York, New York • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2012 · Synced Sep 11, 2026, 6:23 PM EDT
Not yet recruiting Phase 1 Interventional

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

NCT06748872
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma, Synovial Sarcoma
Interventions
Lymphodepletion, TCR-T cells (MDG1015)
Drug · Biological
Lead sponsor
Medigene AG
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2042
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 11, 2026, 6:23 PM EDT
Completed Phase 1 Interventional

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

NCT03652077
View directory record Official record
Conditions
Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Melanoma, Uveal Melanoma, Merkel Cell Carcinoma, Mesothelioma, MSI, Non-small Cell Lung Cancer, NSCLC, Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck, Small Cell Lung Cancer, Renal Cell Carcinoma, RCC, Triple-negative Breast Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
Interventions
INCAGN02390
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Jackson, Mississippi • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 11, 2026, 6:23 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

NCT00436254
View directory record Official record
Conditions
HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
Interventions
pNGVL3-hICD vaccine, sargramostim, flow cytometry, immunologic technique, immunoenzyme technique, protein expression analysis, biopsy
Biological · Other · Genetic + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 11, 2026, 6:23 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer

NCT01686256
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer
Interventions
Tc 99m EC20
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 11, 2026, 6:23 PM EDT